Honor recognizes his advances in predicting in vivo drug responses based on in vitro data ST. LOUIS, MO – Feb. 26, 2014 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Amin Rostami, Pharm.D., Ph.D., FCP, the company’s vice … Continued
ST. LOUIS, MO – Jan. 21, 2014 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Professor Geoff Tucker, its vice president of translational sciences, and co-founder of Simcyp™ and head of its consultancy, has been named president-elect of … Continued
A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin and P-gp inhibitors (e.g. verapamil and its metabolite norverapamil) or P-gp inducers (e.g. rifampicin) is a predictive pharmacokinetic model for digoxin itself. Thus, relevant in vitro metabolic, transporter and inhibitory data incorporated into permeability-limited models, such as the “advanced dissolution, … Continued
